Differential expression of lipoprotein lipase gene in tissues of the rat model with visceral obesity and postprandial hyperlipidemia.
Postprandial hyperlipidemia is frequently accompanied with intra-abdominal visceral accumulation in human subjects. We have found that the decreased lipoprotein lipase (LPL) mass and activity is negatively associated with the amount of visceral fat accumulation. Here, we studied the postprandial hyperlipidemia using the OLETF rat, a model with visceral obesity, in order to clarify the molecular mechanism causing postprandial hyperlipidemia accompanied with visceral obesity. At the same age of 32 weeks, the OLETF rats showed obviously higher plasma leptin, total cholesterol, triglyceride, and HDL-cholesterol levels than the control LETO rats, although the plasma glucose level was not significantly different. Fat-loading test revealed the delayed metabolism of exogenous fat in the OLETF rats compared to the LETO rats, similar to human subjects with visceral obesity. In the obese rats, plasma levels of LPL mass and activities were 60 and 49% of control rats. The expression of LPL gene was decreased in subcutaneous adipose tissues and skeletal muscle of OLETF rats to 40 and 52% compared to those of LETO rats. In OLETF rats, plasma tumor necrosis factor-alpha (TNF-alpha) and insulin levels were increased to 2.0- and 2.3-folds compared to those in control rats. Furthermore, plasma insulin and TNF-alpha levels in OLETF rats were negatively correlated with the expression levels of LPL gene in subcutaneous fat and muscle. These results indicate that decreased LPL mass and activity in the animal model with visceral obesity is possibly caused by decreased expression of LPL gene in tissues mediated by the increased levels of insulin and TNF-alpha. The different expression of LPL gene in tissues associated with the increased levels of insulin and TNF-alpha possibly elucidate the underlying mechanisms involving the postprandial hyperlipidemia observed in visceral obesity.
Hikita
M
M
Second Department of Internal Medicine, Chiba University School of Medicine, Chiba, 260-0856, Japan.
Bujo
H
H
Yamazaki
K
K
Taira
K
K
Takahashi
K
K
Kobayashi
J
J
Saito
Y
Y
D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D015152:Blotting, Northern; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003001:Cloning, Molecular; D004195:Disease Models, Animal; D004224:Diterpenes; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism*; D007328:Insulin / Q000378:metabolism; D020738:Leptin / Q000097:blood; D008071:Lipoprotein Lipase / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism; D009765:Obesity / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D020318:Rats, Long-Evans; D000084562:Retinyl Esters; D013997:Time Factors; D014018:Tissue Distribution; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014801:Vitamin A / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology
D001786:Blood Glucose; D008076:Cholesterol, HDL; D004224:Diterpenes; D007328:Insulin; D020738:Leptin; D012333:RNA, Messenger; D000084562:Retinyl Esters; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D014801:Vitamin A; C014794:retinol palmitate; D002784:Cholesterol; D008071:Lipoprotein Lipase